Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
PFE: BOURLA ALBERT reported buying shares
1 reported purchase of non-derivative securities. Code P includes open-market and private purchases; it does not establish motive.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: BLAYLOCK RONALD E reported buying shares
1 reported purchase of non-derivative securities. Code P includes open-market and private purchases; it does not establish motive.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Buckley Mortimer J reported buying shares
1 reported purchase of non-derivative securities. Code P includes open-market and private purchases; it does not establish motive.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-28. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Financial results
Filed 8-K for an event or period dated 2026-08-04. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: fourth_quarter 2025 lobbying report
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies Executive Order 14297 - Delivering Most-Favored-Nation
Public: Aug 3, 2026, 4:45 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. Issues related to tariff and trade policy. International Supply
Public: Jul 20, 2026, 8:29 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
Medicare and healthcare policy issues as they relate to drug pricing. Issues related to 340B Program General issues with tax reform and foreign tax issues. Issues related to drug consolidation.
Public: Jul 20, 2026, 2:25 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
Intellectual Property Protections and Policy S. 2658 - Medication Affordability and Patent Integrity Act Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027
Public: Jul 20, 2026, 12:39 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income. Issues related to IRC sections 11, 163(j), 951A, and 250.
Public: Jul 20, 2026, 12:31 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
Issues related to FY27 health appropriations Issues related to 340B Program Issues related to drug pricing
Public: Jul 20, 2026, 12:12 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Public: Jul 20, 2026, 11:34 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Jul 20, 2026, 10:28 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Foreign-Trade Zone (FTZ) 43, Notification of Proposed Production Activity; Pfizer Inc.; (Pharmaceutical Products); Kalamazoo and Portage, Michigan
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Jul 20, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Jul 11, 2026, 10:28 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: second_quarter 2026 lobbying report
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues
Public: Jul 9, 2026, 10:30 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Self-Regulatory Organizations; NYSE American LLC; Notice of Filing of a Proposed Rule Change To Amend Rule 903G and 906G
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Jul 7, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing of a Proposed Rule Change To Amend Rules 5.32-O and 5.35-O
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Jul 7, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 34 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Public: Jul 6, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Company disclosure
Filed 8-K for an event or period dated 2026-06-18. Company disclosure.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Leadership change
Filed 8-K for an event or period dated 2026-06-18. Leadership change.
1 congressional household disclosed purchases in the past 90 days. See the trades
Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
Public: Jun 8, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 3:36 PM EST
- USAspending
- Collection in progress56 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 3:27 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:39 PM EST
- Federal Register
- Collection in progress296 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 3:39 PM EST
- Regulations.gov
- Collection in progress30 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 3:39 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST